company background image
NVCR logo

NovoCure NasdaqGS:NVCR Stock Report

Last Price

US$23.70

Market Cap

US$2.4b

7D

12.6%

1Y

-70.3%

Updated

22 May, 2024

Data

Company Financials +

NVCR Stock Overview

An oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally.

NVCR fundamental analysis
Snowflake Score
Valuation1/6
Future Growth1/6
Past Performance0/6
Financial Health4/6
Dividends0/6

NovoCure Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NovoCure
Historical stock prices
Current Share PriceUS$23.70
52 Week HighUS$82.64
52 Week LowUS$10.87
Beta0.49
1 Month Change100.34%
3 Month Change55.51%
1 Year Change-70.32%
3 Year Change-87.48%
5 Year Change-54.81%
Change since IPO29.65%

Recent News & Updates

NovoCure Limited Q1 Earnings: Core Business Accelerating

May 03

Recent updates

NovoCure Limited Q1 Earnings: Core Business Accelerating

May 03

NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?

Apr 08
NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?

NovoCure: Sell The METIS-Inspired Rally

Mar 28

Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

Mar 03
Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio

NovoCure: Stay Cautious Amid Positive Signs

Jan 19

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Nov 16
Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Aug 13
Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?

Is NovoCure (NASDAQ:NVCR) A Risky Investment?

May 15
Is NovoCure (NASDAQ:NVCR) A Risky Investment?

A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)

Apr 24
A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)

Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching

Feb 10
Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Jan 16
Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

NovoCure: See Past Market Myopia And Buy The Dip

Sep 27

Novocure creates new CNS focused franchise to renew growth in brain cancer business

Sep 21

Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

Sep 09
Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?

NovoCure: Does The Reward Outweigh The Risk? I Believe So

Sep 09

NovoCure Q2 2022 Earnings Preview

Jul 27

Is NovoCure (NASDAQ:NVCR) Using Too Much Debt?

May 28
Is NovoCure (NASDAQ:NVCR) Using Too Much Debt?

NovoCure: A Stalwart With More Upsides

May 09

Shareholder Returns

NVCRUS Medical EquipmentUS Market
7D12.6%1.1%1.2%
1Y-70.3%4.2%27.7%

Return vs Industry: NVCR underperformed the US Medical Equipment industry which returned 4.2% over the past year.

Return vs Market: NVCR underperformed the US Market which returned 27.7% over the past year.

Price Volatility

Is NVCR's price volatile compared to industry and market?
NVCR volatility
NVCR Average Weekly Movement10.3%
Medical Equipment Industry Average Movement8.3%
Market Average Movement5.9%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market2.8%

Stable Share Price: NVCR's share price has been volatile over the past 3 months.

Volatility Over Time: NVCR's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20001,453Asaf Danzigerwww.novocure.com

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.

NovoCure Limited Fundamentals Summary

How do NovoCure's earnings and revenue compare to its market cap?
NVCR fundamental statistics
Market capUS$2.45b
Earnings (TTM)-US$192.74m
Revenue (TTM)US$525.66m

4.9x

P/S Ratio

-13.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NVCR income statement (TTM)
RevenueUS$525.66m
Cost of RevenueUS$131.56m
Gross ProfitUS$394.10m
Other ExpensesUS$586.84m
Earnings-US$192.74m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.79
Gross Margin74.97%
Net Profit Margin-36.67%
Debt/Equity Ratio158.5%

How did NVCR perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.